BioScrip (NASDAQ: BIOS) is one of 15 publicly-traded companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it contrast to its competitors? We will compare BioScrip to related companies based on the strength of its analyst recommendations, profitability, risk, institutional ownership, valuation, earnings and dividends.

Earnings and Valuation

This table compares BioScrip and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioScrip $935.59 million -$41.50 million -3.88
BioScrip Competitors $1.06 billion -$22.56 million 778.66

BioScrip’s competitors have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

84.7% of BioScrip shares are owned by institutional investors. Comparatively, 69.6% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by institutional investors. 0.8% of BioScrip shares are owned by company insiders. Comparatively, 10.8% of shares of all “Hospitals, Clinics & Primary Care Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BioScrip and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioScrip -8.42% N/A -8.01%
BioScrip Competitors 3.55% 3.42% 4.26%

Risk & Volatility

BioScrip has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, BioScrip’s competitors have a beta of 0.87, indicating that their average share price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for BioScrip and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioScrip 0 0 4 0 3.00
BioScrip Competitors 59 327 512 9 2.52

BioScrip currently has a consensus price target of $3.75, suggesting a potential upside of 42.05%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 17.30%. Given BioScrip’s stronger consensus rating and higher possible upside, research analysts clearly believe BioScrip is more favorable than its competitors.

Summary

BioScrip competitors beat BioScrip on 8 of the 12 factors compared.

BioScrip Company Profile

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with Analyst Ratings Network's FREE daily email newsletter.